CliffBio
biologic

KEBILIDI

eladocagene exuparvovec-tneq

Loss of exclusivityNovember 2036projected — 12-year biologic exclusivity estimate
CompanyPTC Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameKEBILIDI
Active ingredienteladocagene exuparvovec-tneq
Strength5.6x10^11VG/ML
Dosage formSuspension
RouteIntraputaminal
ModalityBiologic
FDA approvalNovember 2024
Marketing statusRx

More from PTC Therapeutics

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.